A synthetic lethal screen identifies the vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells

Cell Cycle

Volumn 13, Issue 24, 2014, Pages 3839-3856

  Bhattacharjee, V ^a   Zhou, Y ^a   Yen, T J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

BXPC3; Chemosensitization; DNA repair; Gemcitabine; HDAC inhibitors; p300; Panc1; Pancreatic cancer; PARP inhibitor; Rad51 foci; siRNA screen; Stalled replication fork; VDR; Vitamin D receptor

Indexed keywords

GEMCITABINE; PACLITAXEL; RUCAPARIB; SMALL INTERFERING RNA; VITAMIN D RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; CALCITRIOL RECEPTOR; DEOXYCYTIDINE; H2AFX PROTEIN, HUMAN; HISTONE; INDOLE DERIVATIVE; RAD51 PROTEIN; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR P53 BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CONTROLLED STUDY; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GENETIC ASSOCIATION; HOMOLOGOUS RECOMBINATION; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROSTATE CANCER; SENSITIZATION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DNA DAMAGE; DRUG EFFECTS; GENE LIBRARY; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DNA DAMAGE; GENE LIBRARY; HISTONES; HOMOLOGOUS RECOMBINATION; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PANCREATIC NEOPLASMS; RAD51 RECOMBINASE; RECEPTORS, CALCITRIOL; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1;

EID: 84920566345     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.967070     Document Type: Article

References (100)

1. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995; 18:1-6; PMID:7594765
2. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6; PMID:18772397; http://dx.doi.org/10.1126/science.1164368
3. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw 2005; 3:627-36; PMID:16194454
4. van Heek T, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, Wilentz RE. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002; 117:755-65; PMID:12090425; http:// dx.doi.org/10.1309/5RQ0-JCQU-5XF2-51LQ
5. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297:63-4; PMID:12098689; http://dx.doi.org/10.1126/science.1073096
6. Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005; 1756:97-101; PMID:16169155
7. Feldmann G, Rauenzahn S, Maitra A. In vitro models of pancreatic cancer for translational oncology research. Expert Opin Drug Discov 2009; 4:429-43; PMID:20160967; http://dx.doi.org/10.1517/17460440902821657
8. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5:1026-33; PMID:17139287; http://dx.doi.org/10.1038/nrd2086
9. Park JK, Ryu JK, Lee JK, Yoon WJ, Lee SH, Kim YT, Yoon YB. Gemcitabine chemotherapy vs. 5-fluoroura-cil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006; 33:397-402; PMID:17079946; http://dx.doi. org/10.1097/01.mpa.0000236725.26672.be
10. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; PMID:17452677; http://dx.doi. org/10.1200/JCO.2006.07.9525
11. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Boige V, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31:23-9; PMID:23213101; http://dx.doi.org/10.1200/JCO.2012.44.4869
12. Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013; 30:361; PMID:23271209; http:// dx.doi.org/10.1007/s12032-012-0361-2
13. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13:497-501; PMID:22964956.
14. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703; PMID:24131140; http:// dx.doi.org/10.1056/NEJMoa1304369
15. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319:620-4; PMID:18239126; http://dx.doi.org/10.1126/science.1149200
16. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005; 10:565-78; PMID:16177281; http://dx.doi. org/10.1634/theoncologist.10-8-565
17. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18:4266-76; PMID: 22896693; http://dx.doi.org/10.1158/1078-0432.CCR-11-3114
18. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61; PMID:19460966; http://dx.doi.org/10.1126/science.1171362
19. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25:735-47; PMID: 24856585; http://dx.doi.org/10.1016/j.ccr.2014.04.021
20. Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH, et al. Chemoresistance to gemcitabine in hepatoma cells induces epi-thelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget 2013; 4:1999-2009; PMID:24158561.
21. Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, Gladkich J, Nwaeburu CC, Mattern J, Mollenhauer M, et al. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget 2014; 5:5177-89; PMID:25015789
22. Dobzhansky T. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946; 31:269-90.
23. Boone C, Bussey H, Andrews BJ. Exploring genetic interactions and networks with yeast. Nat Rev Genet 2007; 8:437-49; PMID:17510664; http://dx.doi.org/10.1038/nrg2085
24. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-98; PMID:16110319; http://dx.doi.org/10.1038/nrc1691
25. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006; 26:9377-86; PMID:17000754; http://dx. doi.org/10.1128/MCB.01229-06
26. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446:815-9; PMID:17429401; http:// dx.doi.org/10.1038/nature05697
27. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005; 11:323-8; PMID:15671562
28. Hong SP, Kim MJ, Jung MY, Jeon H, Goo J, Ahn SK, Lee SH, Elias PM, Choi EH. Biopositive effects of low-dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 2008; 128:2880-7; PMID:18580964; http://dx.doi.org/10.1038/jid.2008.169
29. Kommagani R, Payal V, Kadakia MP. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem 2007; 282:29847-54; PMID:17716971; http://dx.doi.org/10.1074/jbc.M703641200
30. Tachibana S, Yoshinari K, Chikada T, Toriyabe T, Nagata K, Yamazoe Y. Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. Drug Metab Dispos 2009; 37:1604-10; PMID: 19460946; http://dx.doi.org/10.1124/dmd.109.027219
31. Kittaka A, Yoshida A, Chiang KC, Takano M, Sawada D, Sakaki T, Chen TC. Potent 19-norvitamin D analogs for prostate and liver cancer therapy. Future Med Chem 2012; 4:2049-65; PMID:23157238; http://dx. doi.org/10.4155/fmc.12.130
32. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 2012; 38:161-78; PMID:22525850; http://dx.doi.org/10.1016/j.rdc.2012.03.014
33. Krishnan AV, Swami S, Feldman D. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 2012; 77:1107-12; PMID:22801352; http://dx.doi. org/10.1016/j.steroids.2012.06.005
34. Wang JY, Swami S, Krishnan AV, Feldman D. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate 2012; 72:1628-37; PMID:22457201; http:// dx.doi.org/10.1002/pros.22516
35. Vijayakumar S, Mehta RR, Boerner PS, Packianathan S, Mehta RG. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 2005; 11:362-73; PMID:16259866; http://dx.doi.org/10.1097/00130404-200509000-00002
36. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 1997; 76:1017-20; PMID:9376260; http:// dx.doi.org/10.1038/bjc.1997.501
37. Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010; 9:3022-9; PMID: 20699664; http://dx.doi.org/10.4161/cc.9.15.12381
38. Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab 2011; 25:605-15; PMID: 21872802; http://dx.doi.org/10.1016/j.beem.2011.06.006
39. Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, Messing J, Sheu TJ, Bao BY, Li WX, et al. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res 2012; 72:958-68; PMID:22207345; http://dx.doi.org/10.1158/0008-5472.CAN-11-0042
40. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140
41. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008; 14:5995-6004; PMID:18829478; http://dx.doi.org/10.1158/1078-0432.CCR-08-0291
42. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009; 7:43; PMID:19519883; http://dx.doi.org/10.1186/1479-5876-7-43
43. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799-806; PMID:21389100; http://dx.doi.org/10.1158/1078-0432.CCR-10-2580
44. Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 2012; 13:1072-81; PMID:22825331; http://dx. doi.org/10.4161/cbt.21093
45. Jena S, Lee WP, Doherty D, Thompson PD. PIAS4 represses vitamin D receptor-mediated signaling and acts as an E3-SUMO ligase towards vitamin D receptor. J Steroid Biochem Mol Biol 2012; 132:24-31; PMID:22564762; http://dx.doi.org/10.1016/j.jsbmb.2012.04.006
46. Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, et al. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res 2014; 74:1128-40; PMID:24536047; http://dx.doi.org/10.1158/0008-5472.CAN-13-1915
47. Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 2008; 17:1104-10; PMID:18483332; http://dx.doi.org/10.1158/1055-9965.EPI-07-2713
48. Qi X, Tang J, Pramanik R, Schultz RM, Shirasawa S, Sasazuki T, Han J, ChenG. p38MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 2004; 279:22138-44; PMID:15037631; http://dx.doi.org/10.1074/jbc.M313964200
49. Teichert AE, Elalieh H, Elias PM, Welsh J, Bikle DD. Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. J Invest Dermatol 2011; 131:2289-97; PMID: 21814234; http://dx.doi.org/10.1038/jid.2011.196
50. Sequeira VB, Rybchyn MS, Tongkao-On W, Gor-don-Thomson C, Malloy PJ, Nemere I, Norman AW, Reeve VE, Halliday GM, Feldman D, et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1alpha,25-dihydroxyvitamin D3. Mol Endocrinol 2012; 26:574-82; PMID:22322599; http://dx.doi.org/10.1210/me.2011-1161
51. Beeharry N, Rattner JB, Caviston JP, Yen T. Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override. Cell Cycle 2013; 12:1588-97; PMID:23624842; http://dx.doi.org/10.4161/cc.24740
52. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60:2108-12; PMID:10786669
53. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275:5600-5; PMID:10681541; http://dx.doi. org/10.1074/jbc.275.8.5600
54. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002; 99:14795-800; PMID:12399544; http://dx.doi.org/10.1073/pnas.182557299
55. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66; PMID:18790776; http://dx. doi.org/10.1158/1535-7163.MCT-08-0492
56. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7:2394-404; PMID:18723486; http://dx.doi.org/10.1158/1535-7163.MCT-07-2391
57. Sicinska W, Rotkiewicz P, DeLuca HF. Model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2. J Steroid Biochem Mol Biol 2004; 89-90:107-10; PMID: 15225755.
58. Adachi R, Shulman AI, Yamamoto K, Shimomura I, Yamada S, Mangelsdorf DJ, Makishima M. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol 2004; 18:43-52; PMID:14525957; http://dx.doi.org/10.1210/me.2003-0244
59. Shen Q, Christakos S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 2005; 280:40589-98; PMID:16195230; http://dx.doi.org/10.1074/jbc.M504166200
60. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ ETO oncoprotein. Cancer Cell 2007; 12:457-66; PMID:17996649; http://dx.doi.org/10.1016/j. ccr.2007.09.020
61. Huang X, Tran T, Zhang L, Hatcher R, Zhang P. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005; 102:1065-70; PMID:15650047; http://dx.doi.org/10.1073/pnas.0409130102
62. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 2012; 19:768-78; PMID:22117197; http://dx.doi.org/10.1038/cdd.2011.170
63. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007; 6:1239-48; PMID:17406032; http://dx.doi.org/10.1158/1535-7163.MCT-06-0633
64. Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW. Downregulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther 2010; 335:830-40; PMID:20855443; http://dx.doi.org/10.1124/jpet.110.173146
65. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45-54; PMID:19139112; http://dx.doi.org/10.1158/1535-7163.MCT-08-0662
66. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141:243-54; PMID: 20362325; http://dx.doi.org/10.1016/j.cell.2010.03.012
67. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A, Bonner RF, Bonner WM, Nussenzweig A. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003; 5:675-9; PMID:12792649; http://dx.doi.org/10.1038/ncb1004
68. Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene 2002; 21:8967-80; PMID:12483513; http://dx.doi.org/10.1038/sj.onc.1206136
69. Fragkos M, Jurvansuu J, Beard P. H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 2009; 29:2828-40; PMID:19273588; http://dx. doi.org/10.1128/MCB.01830-08
70. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
71. Gallmeier E, Kern SE. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther 2005; 4:703-6; PMID:16082177; http://dx. doi.org/10.4161/cbt.4.7.1909
72. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4:934-6; PMID:16251802; http://dx.doi.org/10.4161/cbt.4.9.2141
73. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003; 31:4959-64; PMID:12930944; http://dx.doi.org/10.1093/nar/gkg703
74. Gospodinov A, Tsaneva I, Anachkova B. RAD51 foci formation in response to DNA damage is modulated by TIP49. Int J Biochem Cell Biol 2009; 41:925-33; PMID:18834951; http://dx.doi.or/10.1016/j. biocel.2008.09.004
75. Murr R, Loizou JI, Yang YG, Cuenin C, Li H, Wang ZQ, Herceg Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol 2006; 8:91-9; PMID:16341205; http://dx.doi.org/10.1038/ncb1343
76. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, Slater S, Jurutka PW. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008; 66:S98-112; PMID:18844852; http://dx.doi.org/10.1111/j.1753-4887.2008.00093.x
77. Kraus WL, Manning ET, Kadonaga JT. Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol Cell Biol 1999; 19:8123-35; PMID: 10567538
78. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700; PMID:17721433; http://dx.doi.org/10.1038/nrc2196
79. Ogiwara H, Kohno T. CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes. PLoS One 2012; 7:e52810; PMID:23285190; http://dx.doi.org/10.1371/journal.pone.0052810
80. Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer 2013; 13:604; PMID:24359526; http://dx.doi.org/10.1186/1471-2407-13-604
81. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma 2011; 2011:282745; PMID:21197465; http://dx.doi.org/10.1155/2011/282745
82. Kim SW, Kim HJ, Jung DJ, Lee SK, Kim YS, Kim JH, Kim TS, Lee JW. Retinoid-dependent antagonism of serum response factor transactivation mediated by transcriptional coactivator proteins. Oncogene 2001; 20:6638-42; PMID:11641790; http://dx.doi. org/10.1038/sj.onc.1204695
83. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998; 26:2859-64; PMID:9611228; http://dx.doi.org/10.1093/nar/26.12.2859
84. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, Pelicci PG, et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002; 62:7050-8; PMID: 12460926
85. Cao Z, West C, Norton-Wenzel CS, Rej R, Davis FB, Davis PJ, Rej R. Effects of resin or charcoal treatment on fetal bovine serum and bovine calf serum. Endocr Res 2009; 34:101-8; PMID:19878070; http://dx.doi.org/10.3109/07435800903204082
86. Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, Hernandez Z, Haussler CA, Haussler MR, Jurutka PW. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010; 21:1153-61; PMID:20153625; http:// dx.doi.org/10.1016/j.jnutbio.2009.09.012
87. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 2005; 46:46-57; PMID:15489543; http://dx.doi.org/10.1194/jlr.M400294-JLR200
88. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002; 3:224-9; PMID:11882541; http://dx.doi.org/10.1093/embo-reports/kvf053
89. Nakatani Y. Histone acetylases-versatile players. Genes Cells 2001; 6:79-86; PMID:11260253; http://dx.doi.org/10.1046/j.1365-2443.2001.00411.x
90. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 2008; 33:339-49; PMID:18585916; http://dx.doi.org/10.1016/j.tibs.2008.04.015
91. Quivy V, Van Lint C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 2004; 68:1221-9; PMID: 15313420; http://dx.doi.org/10.1016/j.bcp.2004.05.039
92. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A 2001; 98:87-92; PMID:11134513; http://dx.doi.org/10.1073/pnas.98.1.87
93. Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 2010; 10:102-15; PMID:20094045; http://dx.doi.org/10.1038/nrc2781
94. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:Article3; PMID:16646809.
95. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, Karp M, Benjamini Y, Hochberg Y, Laron Z. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995; 45:486-90; PMID:8748093; http://dx.doi.org/10.1016/0306-9877(95)90228-7
96. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25:1105-11; PMID:19289445; http://dx.doi.org/10.1093/bioinformatics/btp120
97. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28:511-5; PMID:20436464; http://dx.doi.org/10.1038/nbt.1621
98. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 2013; 31:46-53; PMID:23222703; http://dx.doi.org/10.1038/nbt.2450
99. Beeharry N, Rattner JB, Bellacosa A, Smith MR, Yen TJ. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2012; 7:e40342; PMID:22768280
100. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003; 160:1017-27; PMID:12668657; http://dx.doi.org/10.1083/jcb.200209065